In today’s healthcare industry, the costs to develop a product are higher than ever before. Research & Development departments focus only on clinical benefits, often leading to sub-optimal commercialization for pharmaceutical firms. Therefore, it is important to optimize R&D efforts by focussing on commercially attractive therapy areas with manageable access hurdles.

At phamax, we help to identify the value of the product at the early stages of the R&D planning by including market access considerations. Our early market access services link the market potential with access requirements, bridging the gap between R&D and Commercial departments for the successful planning of your product.

As our key differentiator, we bring in scientific know-how through our in-house physician team, the Focus Scientific Research Center (FSRC), with access to over 2000 healthcare stakeholders across the globe, supporting your strategy with insights from key medical experts.

In this way, we help you streamline your product development by reducing time and costs, while preparing you for a successful launch.

Contact us today for a CONSULTATION.

Therapy Area Assessment

Our proprietary scientific team, FSRC, works independently with clinical experts across the globe and has excellent levels of therapy knowledge. This enables us to bring you a holistic picture of a therapy area, including its clinical, commercial, and market access aspects, as well as current and future therapies for a disease.

Our investigative product reviews help you identify the unmet needs of various stakeholders, which will grant you further potential opportunities to develop a product. Our experts refine your Research & Development strategy to focus on future patient care and needs. Our experts will also help you optimize your R&D investments. In this way, we help you innovate with a clear understanding of the market and its drivers.

Target Product Profile Modelling and Forecasting

phamax helps you assess the market situation to develop an Ideal Product Profile (IPP), evaluate the degree of alignment between the Target Product Profile (TPP) and the IPP, and estimate the revenue of the product. We create a dynamic TPP to communicate with and align stakeholder expectations, recommend ways to improve the product value proposition and validate estimates on the size of the market opportunity and product potential. Our team streamlines your future investment and development efforts and creates effective clinical development, commercial, and market access plans.

Patient Journey Modelling

The patient journey can be described as the complete story of the patient’s experience in the healthcare system — from the onset of the symptoms to the receipt of the treatment — entailing all the steps in patient care. The patient journey follows the patient pathway, tracking the number of patients from the diagnosis stage.

Patient journey depicts the real-life situation, considering all the unpredictable factors and hurdles, rather than an ideal picture of a patient strictly following treatment guidelines in perfect circumstances. Following such a journey helps healthcare providers easily and effectively identify steps at which healthcare is falling short.

Our service is an unbiased, detailed patient journey, quantifying all patient segments for your product. We identify data gaps across countries and patient segments, redefine commercial focus areas based on identified leverage points (by patient segment), providing an easy tracking tool. Thus, our patient journey allows you to improve launch excellence by targeting the right set of patients with accurate communication.

 

 

 

Behsad Zomorodi headshot

Behsad Zomorodi

Behsad is the founder of phamax and has two decades of industry and consulting experience in the healthcare domain. Before venturing into the consulting space, he served as a National Sales Manager, Business Unit Head and Global Brand Director with foremost enterprises like B-MS, Schering Plough and Novartis.

At phamax, Behsad heads the long term strategic planning, business development and investor relations.

Behsad operates from Zug, Switzerland.

Anand Patil headshot

Anand Patil

Anand is the co-founder of phamax. He has more than fifteen years of experience in the pharmaceutical industry. He has led consulting ventures with top pharmaceutical, product strategies and business planning for large pharmaceutical houses and global consulting practices in India and Switzerland. Before phamax, he was heading a global delivery team at a leading consulting firm in India.

At phamax, Anand manages the Bangalore office and outlines the overall strategy of the company.

Sacha Haymoz headshot

Sacha Haymoz

Sacha is a partner at phamax. He has more than fifteen years of experience in healthcare business analytics, forecasting and commercialization, and FTE and large engagements. He was earlier associated with large corporations like IBM and Hoffmann-La Roche as a strategic marketing and business analytics professional. His expertise spans more than hundred forecast projects. He is also a co-founder of PharmARC, a healthcare consulting firm acquired by IMS Health.

Arun Gowda headshot

Arun Gowda

Arun is a physician by training, with fifteen years of pharmaceutical consulting experience. He has led consulting ventures with top pharmaceutical and FMCG companies. His expertise spans epidemiology studies, literature reviews, whitepapers and poster presentations, business and clinical intelligence studies, market research projects, stakeholder engagement activities, brand positioning (strategy, planning and execution) and digital marketing strategies.

Before phamax, Arun was the Global Product Led for Health and Wellness at Nokia. He managed and monitored the health section for Nokia Life. Arun also has had successful professional associations with PharmARC, MAGNA Health Solutions and United Business Media.

At phamax, Arun heads FSRC (focus scientific research center)

Jayachandra Reddy headshot

Jayachandra Reddy

Jayachandra has more than a decade of experience in marketing analytics and consulting. His experience includes associations with large and medium global pharmaceutical firms on multifarious projects in forecasting, strategy development, business intelligence and portfolio evaluation.

Before phamax, Jayachandra was heading the Commercial Assessment Group of a leading healthcare consulting firm in India. He is experienced in building and managing teams for FTE (Full-Time Equivalent) agreements and other projects.

At phamax, Jayachandra leads the analytics and modelling team

“phamax project leaders have excellent knowledge and their findings are detailed and helpful. The team was instrumental in determining the prices and clinical effectiveness of the products in the markets of our interests.”

“Thank you for the final data. We very much appreciate the fact that you have delivered all the data within the deadlines. Because of your excellent support, we can now also deliver our project in time to our client. It was a pleasure working with you. Looking forward to future projects.”

“The forecast model designed by phamax for one of our projects was very well laid out, very clean. Bearing in mind the success of the first phase of the project, we proposed an expansion. Thank you for the flexibility and the promptness you exhibited in your deliverables.”

“Thank you for everything. It was great to work with you! The step by step approach has been very useful. Good timing and follow up. Great team.”

“phamax met the overall project objectives and encouraged us to engage their services again. They adhered to all the requierments despite unforeseen obstacles and it is great work done by the team.”

“It was so nice working with you on such initiatives, as the outcomes will be pillars for a new line of a business, hopefully with a unique approach. Data analysis and workshops were handled perfectly.”

“Excellent follow up, undestanding and adaptation to client needs. We appeciate the flexibility of phamax and the extra support to deliver the final project as per our expectations.”